MedTrace Logo

A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

NCT00142350 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2016-09-12

No results posted yet for this study

Summary

To investigate the superiority of a combination of irinotecan and cisplatin and the non-inferiority of S-1 compared to continuous infusion of 5-FU in advanced gastric cancer

Conditions

Interventions

DRUG

continuous infusion of 5-fluorouracil

DRUG

combination of irinotecan and cisplatin

DRUG

oral administration of S-1

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Taiho Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Yakult Honsha Co., LTD

    collaborator INDUSTRY

  • Japan Clinical Oncology Group

    lead OTHER

Principal Investigators

  • Atsushi Ohtsu, MD · National Cancer Centr Hospital East

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Completion
2007-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142350 on ClinicalTrials.gov